Author:
Bogers Jan P.A.M.,Bui Hong,Herruer Martien,Cohen Dan
Subject
Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology
Reference11 articles.
1. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy;Cohen;J. Clin. Psychiat.,2012
2. European Medicines Agency (EMA), 2002. Committee for proprietary medicinal products (CPMP): summary information on referral opinion following arbitration pursuant to article 30 of council directive 2001/83/EC for Leponex and associated names. 〈http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Leponex_30/WC500010966.pdf〉 (accessed 13.05.14.).
3. Food and Drug Administration (FDA), 2002. Clozaril. 〈http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/19758se1-047_Clozaril_lbl.pdf〉 (accessed 13.05.14.).
4. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in the treatment of schizophrenia;Gören;Psychiatr. Serv.,2013
5. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation;Howes;Brit. J. Psychiat.,2012
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献